JP7316227B2 - がん治療のためのｒａｃ１阻害剤及びその使用 - Google Patents
がん治療のためのｒａｃ１阻害剤及びその使用 Download PDFInfo
- Publication number
- JP7316227B2 JP7316227B2 JP2019567573A JP2019567573A JP7316227B2 JP 7316227 B2 JP7316227 B2 JP 7316227B2 JP 2019567573 A JP2019567573 A JP 2019567573A JP 2019567573 A JP2019567573 A JP 2019567573A JP 7316227 B2 JP7316227 B2 JP 7316227B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- dcm
- formula
- groups
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 title description 9
- 239000003112 inhibitor Substances 0.000 title description 7
- 238000011275 oncology therapy Methods 0.000 title 1
- 102000010838 rac1 GTP Binding Protein Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 105
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 46
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 262
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 92
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 66
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 60
- 239000011541 reaction mixture Substances 0.000 description 49
- 238000003756 stirring Methods 0.000 description 48
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- 235000019439 ethyl acetate Nutrition 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 34
- 238000004896 high resolution mass spectrometry Methods 0.000 description 33
- 239000012043 crude product Substances 0.000 description 31
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 30
- YXBJMDMSTRMFRE-UHFFFAOYSA-N n-[4-[(2,5-dimethoxyphenyl)sulfamoyl]phenyl]-3-(4-methylphenyl)sulfanylpropanamide Chemical compound COC1=CC=C(OC)C(NS(=O)(=O)C=2C=CC(NC(=O)CCSC=3C=CC(C)=CC=3)=CC=2)=C1 YXBJMDMSTRMFRE-UHFFFAOYSA-N 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- 239000002904 solvent Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 27
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- 239000010410 layer Substances 0.000 description 25
- 238000010898 silica gel chromatography Methods 0.000 description 25
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 24
- 101150058540 RAC1 gene Proteins 0.000 description 22
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 21
- 239000011734 sodium Substances 0.000 description 21
- 238000001035 drying Methods 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- 239000012300 argon atmosphere Substances 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 125000005843 halogen group Chemical group 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 230000005587 bubbling Effects 0.000 description 15
- WNZPCDJZVOAORM-UHFFFAOYSA-N 4-amino-n-(2,5-dimethoxyphenyl)benzenesulfonamide Chemical compound COC1=CC=C(OC)C(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1 WNZPCDJZVOAORM-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- 235000017557 sodium bicarbonate Nutrition 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- RBTBHWRJRBZCIE-UHFFFAOYSA-N 3-(4-methylphenyl)sulfanylpropanoyl chloride Chemical compound CC1=CC=C(SCCC(Cl)=O)C=C1 RBTBHWRJRBZCIE-UHFFFAOYSA-N 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 11
- 229940124530 sulfonamide Drugs 0.000 description 11
- XBXWZQQQBVBPAC-UHFFFAOYSA-N 4-amino-n-(2-methoxyphenyl)benzenesulfonamide Chemical compound COC1=CC=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 XBXWZQQQBVBPAC-UHFFFAOYSA-N 0.000 description 10
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 150000001408 amides Chemical group 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- ZRYGVBRPRKRFHJ-UHFFFAOYSA-N 3-(4-methylphenyl)sulfanylpropanoic acid Chemical compound CC1=CC=C(SCCC(O)=O)C=C1 ZRYGVBRPRKRFHJ-UHFFFAOYSA-N 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 9
- 239000007928 intraperitoneal injection Substances 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- 230000009401 metastasis Effects 0.000 description 9
- -1 sulfonamide compounds Chemical class 0.000 description 9
- 150000003456 sulfonamides Chemical class 0.000 description 9
- 125000004001 thioalkyl group Chemical group 0.000 description 9
- 102000007469 Actins Human genes 0.000 description 8
- 108010085238 Actins Proteins 0.000 description 8
- 102100039832 Ribonuclease pancreatic Human genes 0.000 description 8
- DEFBCZWQLILOJF-UHFFFAOYSA-N NSC 23766 Chemical compound CCN(CC)CCCC(C)NC1=NC(C)=CC(NC=2C=C3C(N)=CC(C)=NC3=CC=2)=N1 DEFBCZWQLILOJF-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000003915 cell function Effects 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- ZAWZAMLFHQDVRM-UHFFFAOYSA-N n-(2,4-dimethoxyphenyl)-4-nitrobenzenesulfonamide Chemical compound COC1=CC(OC)=CC=C1NS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 ZAWZAMLFHQDVRM-UHFFFAOYSA-N 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 102220198117 rs1057519874 Human genes 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- QUMSWNAZSQNCMN-UHFFFAOYSA-N COC1=C(C=C(C=C1)OC)NS(=O)(=O)C1=CC=C(C=C1)NC(CCS(=O)(=O)C1=CC=C(C)C=C1)=O Chemical compound COC1=C(C=C(C=C1)OC)NS(=O)(=O)C1=CC=C(C=C1)NC(CCS(=O)(=O)C1=CC=C(C)C=C1)=O QUMSWNAZSQNCMN-UHFFFAOYSA-N 0.000 description 5
- HFHVJURMMJPXFL-UHFFFAOYSA-N N-[4-[(2,5-dimethoxyphenyl)sulfamoyl]phenyl]-3-trimethylsilylprop-2-ynamide Chemical compound COC1=C(C=C(C=C1)OC)NS(=O)(=O)C1=CC=C(C=C1)NC(C#C[Si](C)(C)C)=O HFHVJURMMJPXFL-UHFFFAOYSA-N 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000012455 biphasic mixture Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000004709 cell invasion Effects 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000037819 metastatic cancer Diseases 0.000 description 5
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- CULAOYRJHZVXNW-UHFFFAOYSA-N n-(2,5-dimethoxyphenyl)-4-nitrobenzenesulfonamide Chemical compound COC1=CC=C(OC)C(NS(=O)(=O)C=2C=CC(=CC=2)[N+]([O-])=O)=C1 CULAOYRJHZVXNW-UHFFFAOYSA-N 0.000 description 5
- YEQLXQLWQPTIHO-UHFFFAOYSA-N n-(2-methoxyphenyl)-4-nitrobenzenesulfonamide Chemical compound COC1=CC=CC=C1NS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 YEQLXQLWQPTIHO-UHFFFAOYSA-N 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- KZGBEZFUYXJNQV-UHFFFAOYSA-N C1=C(C=CC(=C1NC(=O)C1=CC=C(NC(=O)CCSC2=CC=C(C=C2)C)C=C1)OC)OC Chemical compound C1=C(C=CC(=C1NC(=O)C1=CC=C(NC(=O)CCSC2=CC=C(C=C2)C)C=C1)OC)OC KZGBEZFUYXJNQV-UHFFFAOYSA-N 0.000 description 4
- OKTXURGXZWGLKC-UHFFFAOYSA-N C1=C(C=CC(=C1NS(=O)(=O)C1=CC=C(NC(=O)CCCC2=CC=C(C)C=C2)C=C1)OC)OC Chemical compound C1=C(C=CC(=C1NS(=O)(=O)C1=CC=C(NC(=O)CCCC2=CC=C(C)C=C2)C=C1)OC)OC OKTXURGXZWGLKC-UHFFFAOYSA-N 0.000 description 4
- ZPMPZUZHZFCFAL-UHFFFAOYSA-N C1=C(C=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CCSC2=CC=C(C=C2)C)C=C1)OC Chemical compound C1=C(C=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CCSC2=CC=C(C=C2)C)C=C1)OC ZPMPZUZHZFCFAL-UHFFFAOYSA-N 0.000 description 4
- VHEIUFMZCHBCEP-UHFFFAOYSA-N C1=C(NS(=O)(=O)C2=CC=C(C=C2)NC(=O)CCSC2=CC=C(C)C=C2)C(OC)=CC=C1 Chemical compound C1=C(NS(=O)(=O)C2=CC=C(C=C2)NC(=O)CCSC2=CC=C(C)C=C2)C(OC)=CC=C1 VHEIUFMZCHBCEP-UHFFFAOYSA-N 0.000 description 4
- DEVNBMQTZNEKCU-UHFFFAOYSA-N COC1=C(C=C(C=C1)OC)N(S(=O)(=O)C1=CC=C(C=C1)NC(CCSC1=CC=C(C=C1)C)=O)C Chemical compound COC1=C(C=C(C=C1)OC)N(S(=O)(=O)C1=CC=C(C=C1)NC(CCSC1=CC=C(C=C1)C)=O)C DEVNBMQTZNEKCU-UHFFFAOYSA-N 0.000 description 4
- WAPCTLOEWMKRRK-UHFFFAOYSA-N COC1=C(C=C(C=C1)OC)NS(=O)(=O)C1=CC=C(C=C1)NC(CCS(=O)C1=CC=C(C=C1)C)=O Chemical compound COC1=C(C=C(C=C1)OC)NS(=O)(=O)C1=CC=C(C=C1)NC(CCS(=O)C1=CC=C(C=C1)C)=O WAPCTLOEWMKRRK-UHFFFAOYSA-N 0.000 description 4
- RAQRILHPRNUPAD-UHFFFAOYSA-N COc1ccc(OC)c(NS(=O)(=O)c2ccc(NC(=O)CCl)cc2)c1 Chemical compound COc1ccc(OC)c(NS(=O)(=O)c2ccc(NC(=O)CCl)cc2)c1 RAQRILHPRNUPAD-UHFFFAOYSA-N 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- GTXMNDLAOWNJLJ-UHFFFAOYSA-N N-[4-[(2,5-dimethoxyphenyl)sulfamoyl]phenyl]prop-2-ynamide Chemical compound C(C#C)(=O)NC1=CC=C(C=C1)S(NC1=C(C=CC(=C1)OC)OC)(=O)=O GTXMNDLAOWNJLJ-UHFFFAOYSA-N 0.000 description 4
- JQBCWUOYWCJJGR-UHFFFAOYSA-N N-[4-[(2-fluorophenyl)sulfamoyl]phenyl]-3-(4-methylphenyl)sulfanylpropanamide Chemical compound Cc1ccc(SCCC(=O)Nc2ccc(cc2)S(=O)(=O)Nc2ccccc2F)cc1 JQBCWUOYWCJJGR-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- WEBACMIYOUMYES-UHFFFAOYSA-N ethyl N-[4-[(2,5-dimethoxyphenyl)sulfamoyl]phenyl]carbamate Chemical compound CCOC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1cc(OC)ccc1OC WEBACMIYOUMYES-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- DOFJKIFMXFUSCX-UHFFFAOYSA-N n-(3-methoxyphenyl)-4-nitrobenzenesulfonamide Chemical compound COC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)[N+]([O-])=O)=C1 DOFJKIFMXFUSCX-UHFFFAOYSA-N 0.000 description 4
- UCMKMBTUGXIGPL-UHFFFAOYSA-N n-[4-[(2,4-dimethoxyphenyl)sulfamoyl]phenyl]-3-(4-methylphenyl)sulfanylpropanamide Chemical compound COC1=CC(OC)=CC=C1NS(=O)(=O)C(C=C1)=CC=C1NC(=O)CCSC1=CC=C(C)C=C1 UCMKMBTUGXIGPL-UHFFFAOYSA-N 0.000 description 4
- SVJSNVAKHGTNQS-UHFFFAOYSA-N n-[4-[(2,5-dimethoxyphenyl)sulfamoyl]phenyl]-2-(4-methylphenyl)sulfanylacetamide Chemical compound COC1=CC=C(OC)C(NS(=O)(=O)C=2C=CC(NC(=O)CSC=3C=CC(C)=CC=3)=CC=2)=C1 SVJSNVAKHGTNQS-UHFFFAOYSA-N 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- CYFNPWLREAHHLY-UHFFFAOYSA-N 4-amino-n-(2,4-dimethoxyphenyl)benzenesulfonamide Chemical compound COC1=CC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 CYFNPWLREAHHLY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- SOXPERSPXCYAKB-UHFFFAOYSA-N COC1=C(C=C(C=C1)OC)NS(=O)(=O)C1=CC=C(C=C1)NC(C=C)=O Chemical compound COC1=C(C=C(C=C1)OC)NS(=O)(=O)C1=CC=C(C=C1)NC(C=C)=O SOXPERSPXCYAKB-UHFFFAOYSA-N 0.000 description 3
- NECDUGZIDZSJDT-UHFFFAOYSA-N COC1=C(C=C(C=C1)OC)NS(=O)(=O)C1=CC=C(C=C1)NC(CCOC1=CC=C(C=C1)C)=O Chemical compound COC1=C(C=C(C=C1)OC)NS(=O)(=O)C1=CC=C(C=C1)NC(CCOC1=CC=C(C=C1)C)=O NECDUGZIDZSJDT-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- CJGQUWNYELOFGE-UHFFFAOYSA-N N-[4-[(2,5-dimethoxyphenyl)sulfamoyl]phenyl]propanamide Chemical compound C(CC)(=O)NC1=CC=C(C=C1)S(NC1=C(C=CC(=C1)OC)OC)(=O)=O CJGQUWNYELOFGE-UHFFFAOYSA-N 0.000 description 3
- MTXBKGYSSGCFSJ-UHFFFAOYSA-N N-[4-[(2-methoxyphenyl)sulfamoyl]phenyl]-2-(4-methylphenyl)sulfanylacetamide Chemical compound COc1ccccc1NS(=O)(=O)c1ccc(NC(=O)CSc2ccc(C)cc2)cc1 MTXBKGYSSGCFSJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 3
- 238000000451 chemical ionisation Methods 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 101001110283 Canis lupus familiaris Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000001448 anilines Chemical group 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 102000030938 small GTPase Human genes 0.000 description 2
- 108060007624 small GTPase Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 description 1
- GEQNZVKIDIPGCO-UHFFFAOYSA-N 2,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C(OC)=C1 GEQNZVKIDIPGCO-UHFFFAOYSA-N 0.000 description 1
- NAZDVUBIEPVUKE-UHFFFAOYSA-N 2,5-dimethoxyaniline Chemical compound COC1=CC=C(OC)C(N)=C1 NAZDVUBIEPVUKE-UHFFFAOYSA-N 0.000 description 1
- LSECOAJFCKFQJG-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)-5-[5-[7-(trifluoromethyl)quinolin-4-yl]sulfanylpentoxy]pyran-4-one;dihydrochloride Chemical compound Cl.Cl.C=1C=NC2=CC(C(F)(F)F)=CC=C2C=1SCCCCCOC(C(C=1)=O)=COC=1CN1CCOCC1 LSECOAJFCKFQJG-UHFFFAOYSA-N 0.000 description 1
- GNDKYAWHEKZHPJ-UHFFFAOYSA-N 2-nitrobenzenesulfonimidic acid Chemical class NS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O GNDKYAWHEKZHPJ-UHFFFAOYSA-N 0.000 description 1
- GNPISAHACGIXLZ-UHFFFAOYSA-N 3-(4-methylphenoxy)propanoic acid Chemical compound CC1=CC=C(OCCC(O)=O)C=C1 GNPISAHACGIXLZ-UHFFFAOYSA-N 0.000 description 1
- HXZLEMZJRUFEKH-UHFFFAOYSA-N 3-(4-methylphenyl)sulfonylpropanoic acid Chemical compound CC1=CC=C(S(=O)(=O)CCC(O)=O)C=C1 HXZLEMZJRUFEKH-UHFFFAOYSA-N 0.000 description 1
- HRQOMRLFGYDXJO-UHFFFAOYSA-N 3-(4-methylphenyl)sulfonylpropanoyl chloride Chemical compound CC1=CC=C(S(=O)(=O)CCC(Cl)=O)C=C1 HRQOMRLFGYDXJO-UHFFFAOYSA-N 0.000 description 1
- NONFLFDSOSZQHR-UHFFFAOYSA-N 3-(trimethylsilyl)propionic acid Chemical compound C[Si](C)(C)CCC(O)=O NONFLFDSOSZQHR-UHFFFAOYSA-N 0.000 description 1
- CIQYUDZNFLTUTN-UHFFFAOYSA-N 3-trimethylsilylprop-2-ynoyl chloride Chemical compound C[Si](C)(C)C#CC(Cl)=O CIQYUDZNFLTUTN-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- HGFAYEMEDMUNOS-UHFFFAOYSA-N 4-(4-methylphenyl)sulfanylbutanoic acid Chemical compound CC1=CC=C(SCCCC(O)=O)C=C1 HGFAYEMEDMUNOS-UHFFFAOYSA-N 0.000 description 1
- SJAKVVJVZDEKKP-UHFFFAOYSA-N 4-amino-n-(2,5-dimethoxyphenyl)benzamide Chemical compound COC1=CC=C(OC)C(NC(=O)C=2C=CC(N)=CC=2)=C1 SJAKVVJVZDEKKP-UHFFFAOYSA-N 0.000 description 1
- CEWDGJUHWDSLRV-UHFFFAOYSA-N 4-amino-n-(2-fluorophenyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=C1F CEWDGJUHWDSLRV-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- HKRUDMCZGNMMOV-UHFFFAOYSA-N C1(=CC=C(C=C1)SCCCC(=O)Cl)C Chemical compound C1(=CC=C(C=C1)SCCCC(=O)Cl)C HKRUDMCZGNMMOV-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101000741974 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein Proteins 0.000 description 1
- 101000817237 Homo sapiens Protein ECT2 Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027462 Metastases to ovary Diseases 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 229910004844 Na2B4O7.10H2O Inorganic materials 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 102100038634 Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100040437 Protein ECT2 Human genes 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010001288 T-Lymphoma Invasion and Metastasis-inducing Protein 1 Proteins 0.000 description 1
- 102000002154 T-Lymphoma Invasion and Metastasis-inducing Protein 1 Human genes 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 102220383968 c.275A>T Human genes 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical compound OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102220198276 rs1057519948 Human genes 0.000 description 1
- 102220074603 rs778256566 Human genes 0.000 description 1
- 230000022932 ruffle assembly Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305664.9 | 2017-06-06 | ||
| EP17305664.9A EP3412652A1 (en) | 2017-06-06 | 2017-06-06 | Inhibitors of rac1 and uses thereof for treating cancers |
| PCT/EP2018/064928 WO2018224563A1 (en) | 2017-06-06 | 2018-06-06 | Inhibitors of rac1 and uses thereof for treating cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524136A JP2020524136A (ja) | 2020-08-13 |
| JP2020524136A5 JP2020524136A5 (enExample) | 2021-07-26 |
| JP7316227B2 true JP7316227B2 (ja) | 2023-07-27 |
Family
ID=59034696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567573A Active JP7316227B2 (ja) | 2017-06-06 | 2018-06-06 | がん治療のためのｒａｃ１阻害剤及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11795144B2 (enExample) |
| EP (2) | EP3412652A1 (enExample) |
| JP (1) | JP7316227B2 (enExample) |
| CA (1) | CA3066031A1 (enExample) |
| WO (1) | WO2018224563A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3412651A1 (en) * | 2017-06-06 | 2018-12-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibitors of rac1 and uses thereof for inducing bronchodilatation |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006508906A (ja) | 2002-07-05 | 2006-03-16 | サイクラセル・リミテッド | ビスアリールスルホンアミド化合物及び癌の治療におけるその使用 |
| JP2011032294A (ja) | 2003-08-08 | 2011-02-17 | Vertex Pharmaceuticals Inc | 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物 |
| US20110201609A1 (en) | 2008-06-30 | 2011-08-18 | H. Lee Moffitt Cancer Center & Research Institute | Proteasome inhibitors for selectively inducing apoptosis in cancer cells |
| WO2013009799A1 (en) | 2011-07-11 | 2013-01-17 | Beth Israel Deaconess Medical Center, Inc. | Vitamin d receptor agonists and uses thereof |
| WO2015138377A1 (en) | 2014-03-10 | 2015-09-17 | The University Of Chicago | Methods of treating cancer using rad51small molecule stimulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2192490A (en) * | 1936-03-21 | 1940-03-05 | Hoffmann La Roche | Derivatives of 4-aminobenzenesulphonamides and process for the manufacture of same |
| US2407309A (en) * | 1942-02-04 | 1946-09-10 | Squibb & Sons Inc | Chemotherapeutic agents of the sulphonamide type |
| US5939451A (en) * | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
| JPH10193554A (ja) | 1997-01-16 | 1998-07-28 | Fuji Photo Film Co Ltd | ネガ型画像記録材料 |
| US6521658B1 (en) * | 1999-05-28 | 2003-02-18 | Abbott Laboratories | Cell proliferation inhibitors |
| CA2379526A1 (en) | 2002-03-28 | 2003-09-28 | Gilles Sauve | Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors |
| CN101429142B (zh) * | 2008-12-17 | 2011-11-16 | 山东大学 | 一种含氮多羟基芳香类化合物及其制备方法和应用 |
| US20110275635A1 (en) * | 2009-01-09 | 2011-11-10 | The Uab Research Foundation | Small molecule inhibitors of nads, namnat, and nmnat |
| WO2010111713A2 (en) * | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | N-linked glycan biosynthesis modulators |
| WO2012142698A1 (en) * | 2011-04-20 | 2012-10-26 | Universite Laval | Alkylurea derivatives active against cancer cells |
-
2017
- 2017-06-06 EP EP17305664.9A patent/EP3412652A1/en not_active Withdrawn
-
2018
- 2018-06-06 EP EP18728643.0A patent/EP3634949B1/en active Active
- 2018-06-06 CA CA3066031A patent/CA3066031A1/en active Pending
- 2018-06-06 WO PCT/EP2018/064928 patent/WO2018224563A1/en not_active Ceased
- 2018-06-06 JP JP2019567573A patent/JP7316227B2/ja active Active
- 2018-06-06 US US16/619,311 patent/US11795144B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006508906A (ja) | 2002-07-05 | 2006-03-16 | サイクラセル・リミテッド | ビスアリールスルホンアミド化合物及び癌の治療におけるその使用 |
| JP2011032294A (ja) | 2003-08-08 | 2011-02-17 | Vertex Pharmaceuticals Inc | 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物 |
| US20110201609A1 (en) | 2008-06-30 | 2011-08-18 | H. Lee Moffitt Cancer Center & Research Institute | Proteasome inhibitors for selectively inducing apoptosis in cancer cells |
| WO2013009799A1 (en) | 2011-07-11 | 2013-01-17 | Beth Israel Deaconess Medical Center, Inc. | Vitamin d receptor agonists and uses thereof |
| WO2015138377A1 (en) | 2014-03-10 | 2015-09-17 | The University Of Chicago | Methods of treating cancer using rad51small molecule stimulators |
Non-Patent Citations (11)
| Title |
|---|
| 2-Chloro-N-[4-[[(2,5-dimethoxyphenyl)amino]sulfonyl]phenyl]acetamide，SR Chemical Library，2003年，CAS登録番号528580-84-9 |
| 4-Amino-5-(arylaminomethyl)-2-(methylthio)furo[2,3-d]pirimidines via Mitsunobu Reaction of 4-Amino-5-(hydroxymethyl)-2-(methylthio)furo[2,3-d]pirimidine with N-Mesyl- and N-Nosylarylamines，Synthesis，2012年，(2012), 44, p1329-1338 |
| 4-Amino-N-(2,4-dimethoxyphenyl)benzenesulfonamide，SR Chemical Library，2007年，CAS登録番号952946-68-8 |
| Ethyl N-[4-[[(2,5-dimethoxyphenyl)amino]sulfonyl]phenyl]carbamate，SR Chemical Library，2007年，CAS登録番号943082-65-3 |
| Highly specific N-monomethylation of primary aromatic amines，Tetrahedron，2006年，(2006), 62(25), 6100-6106 |
| N-(2,4-Dimethoxyphenyl)-4-nitrobenzenesulfonamide ，SR CAS Client Services，2001年，CAS登録番号331240-24-5 |
| N-[4-[[(2,4-Dimethoxyphenyl)amino]sulfonyl]phenyl]-3-[(4-methylphenyl)thio]propanamide，SR Chemical Library，2004年，CAS登録番号642998-77-4 |
| N-[4-[[(2,5-Dimethoxyphenyl)amino]sulfonyl]phenyl]-3-[(4-methylphenyl)thio]propanamide，SR Chemical Library，2004年，CAS登録番号694515-65-6 |
| NATARAJAN A，NOVEL ARYLSULFOANILIDE-OXINDOLE HYBRID AS AN ANTICANCER AGENT THAT INHIBITS TRANSLATION INITIATION，JOURNAL OF MEDICINAL CHEMISTRY，2004年10月07日，VOL:47, NR:21,，PAGE(S):4979 - 4982，http://dx.doi.org/10.1021/jm0496234 |
| SALUM LIVIA B，N-(1'-NAPHTHYL)-3,4,5-TRIMETHOXYBENZOHYDRAZIDE AS MICROTUBULE DESTABILIZER: SYNTHESIS, 以下備考，EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY，2015年02月23日，VOL:96,，PAGE(S):504 - 518，http://dx.doi.org/10.1016/j.ejmech.2015.02.041，CYTOTOXICITY, INHIBITION OF CELL MIGRATION AND IN VIVO ACTIVITY AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA |
| ZHENG X，ANALGESIC AGENTS WITHOUT GASTRIC DAMAGE: DESIGN AND SYNTHESIS OF STRUCTURALLY 以下備考，BIOORGANIC & MEDICINAL CHEMISTRY，英国，PERGAMON，2006年12月12日，VOL:15, NR:2,，PAGE(S):1014 - 1021，http://dx.doi.org/10.1016/j.bmc.2006.10.029，SIMPLE BENZENESULFONANILIDE-TYPE CYCLOOXYGENASE-1-SELECTIVE INHIBITORS |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018224563A9 (en) | 2021-04-22 |
| US20200095199A1 (en) | 2020-03-26 |
| EP3634949B1 (en) | 2025-03-19 |
| US11795144B2 (en) | 2023-10-24 |
| EP3412652A1 (en) | 2018-12-12 |
| CA3066031A1 (en) | 2018-12-13 |
| JP2020524136A (ja) | 2020-08-13 |
| EP3634949A1 (en) | 2020-04-15 |
| WO2018224563A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500783A (ja) | ヒストンデアセチラーゼ阻害剤 | |
| HRP970680A2 (en) | New ketobenzamides and their use | |
| CA2843211C (en) | Thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments | |
| KR19980086847A (ko) | 설포닐아미노카복실산 | |
| JP4979583B2 (ja) | 新規のヒストンデアセチラーゼ阻害剤 | |
| KR20010042839A (ko) | 시스테인 프로테아제를 억제하는 효과를 나타내고헤테로시클릭 치환체가 있는 신규 아미드 | |
| KR20140106750A (ko) | Mogat-2 억제제로서 유용한 벤질 술폰아미드 유도체 | |
| AU2008309269A1 (en) | Novel histone deacetylase inhibitors | |
| KR101497113B1 (ko) | Ｈｉｆ-1 활성을 저해하는 아릴옥시페녹시아크릴계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 | |
| JP7316227B2 (ja) | がん治療のためのｒａｃ１阻害剤及びその使用 | |
| WO2009066072A2 (en) | Compound | |
| CN119874637A (zh) | 多酚酪氨酸酶抑制剂及其制备方法和应用 | |
| JP2019521193A (ja) | 抗癌剤としての４−アニリノ−キノリン化合物 | |
| CN114929675A (zh) | 作为粘着斑激酶抑制剂的新型金刚烷衍生物 | |
| JP7247114B2 (ja) | 気管支拡張を誘発するためのｒａｃ１阻害剤及びその使用 | |
| CN106496132B (zh) | N-(4-取代苯基)-2-取代乙酰胺类化合物及其作为sirt2蛋白抑制剂的用途 | |
| JPWO2005035471A1 (ja) | エーテル誘導体 | |
| RU2834688C1 (ru) | Производные 4-((арил)(метил)амино)хиназолин-7-карбоновой кислоты с противоопухолевым действием и способ их получения | |
| FR2943675A1 (fr) | Composes anticancereux, leur preparation et leur application en therapeutique | |
| CN113929591A (zh) | 具有抗增殖活性的抑制剂 | |
| CN120774848A (zh) | 吡唑类化合物及其制备方法、药物组合物和应用 | |
| HK1063016A1 (zh) | Cdc25磷酸酶抑制劑 | |
| HK1063016B (en) | Cdc25 phosphatase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210603 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210603 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211104 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220104 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220328 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220704 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221025 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230420 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230627 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230714 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7316227 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |